Lilly posts sales below estimates
(Reuters) - U.S. drugmaker Eli Lilly and Co (LLY.N) reported lower-than-expected quarterly revenue on Thursday, hurt by disappointing sales of its cancer and diabetes drugs.
Lilly said it earned $728 million, or 68 cents per share, in the first quarter. It had profit of $1.55 billion, or $1.42 per share, a year earlier, when Lilly posted special gains from transferring rights to a diabetes drug.
Excluding special items, Lilly earned 70 cents per share, matching the average estimate of analysts, as compiled by Thomson Reuters I/B/E/S.
Revenue fell 16 percent to $4.68 billion while Wall Street expected $4.8 billion.
Lilly said it still expected earnings of $2.72 to $2.80 per share, excluding items, in full-year 2014.
(Corrects last paragraph to show 2014 profit outlook is unchanged rather than cut; removes reference to lowered outlook in headline and first paragraph)
(Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe)
- More troops deployed in Ferguson to guard against fresh riots |
- Merkel hits diplomatic dead-end with Putin
- Jewish-nation bill frays Israel's delicate social fabric
- Ukraine reports new arrivals of Russian supplies for eastern rebels |
- Gunshots echo as violence returns to Ferguson, protests across U.S.
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video